Get started
Author

Ze Su

Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
2025 · Da-Long Yang, Lin Ye, et al. · Hepatology · 34
Systematic treatment in unresectable hepatocellular carcinoma: The most concerns
2024 · Jian-Hong Zhong, Kang Chen, et al. · iLiver · 10
Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004)
2025 · Da-Long Yang, Yi-He Yan, et al. · JHEP Reports · 9
PDF
Survival benefit of hepatectomy after complete or partial response to conversion therapy in unresectable hepatocellular carcinoma (GUIDANCE003): a multi-center study
2025 · Da-Long Yang, Ning Peng, et al. · Liver Cancer · 9
PDF
Immune Checkpoint Inhibitor Rechallenge in Unresectable Hepatocellular Carcinoma: A Multicenter Efficacy and Safety Study
2026 · Jing-Kun Chen, Jia-Liang Wei, et al. · Liver Cancer · 6
PDF
Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
2025 · Da-Long Yang, Lin Ye, et al. · Hepatology · 4
The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection
2025 · Ning Peng, Lin-Feng Mao, et al. · Frontiers in Immunology · 4
PDF
Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006)
2025 · Liang Ma, Da-Long Yang, et al. · Liver Cancer · 3
PDF
Letter: Comparison of the Efficacy of Adjuvant PD ‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) Related HCC Versus Other Aetiologies
2025 · Jia‐Yong Su, Kang Chen, et al. · Alimentary Pharmacology & Therapeutics · 2
PDF
Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective Study
2026 · Lin Ye, Guo-Xing Liu, et al. · Liver Cancer · 1
Joint association of estimated glucose disposal rate and systemic inflammation response index with mortality in metabolic-dysfunction associated steatotic liver disease: evidence from two cohort studies
2026 · Guodong Yang, Xin Qiu, et al. · Cardiovascular Diabetology · 1
PDF
Efficacy and safety of adjuvant transarterial chemoembolization in high-risk HCC after curative hepatectomy: a phase III RCT protocol
2026 · Chao-Man Huang, Shu-Chang Chen, et al. · iLiver · 1
Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002)
2026 · Da-Long Yang, Chuang Qin, et al. · Communications Medicine · 1
PDF
Detection of EBV DNA in clinically ill patients from 2013 to 2023 in Beijing, China
2025 · Ze Su, Ziran Wang, et al. · Frontiers in Microbiology · 1
PDF
Impact of Clonorchis sinensis infection on long-term survival after curative resection for hepatocellular carcinoma: A multicenter cohort study
2025 · Shuang Shen, Xin Qiu, et al. · PLoS neglected tropical diseases · 1
PDF
Value of tumor burden score combined with alpha-fetoprotein stratification in transarterial chemoembolization plus tyrosine kinase inhibitors and immune checkpoint inhibitors as triple conversion therapy for patients with initially unresectable hepatocellular carcinoma: a multicenter retrospective study (GUIDANCE010)
2026 · Zhi-Cheng Li, Cai-Hua Li, et al. · European Journal of Surgical Oncology
Supplemental Material for: Feasibility of achieving a tumor- and drug-free state through conversion therapy followed by curative hepatectomy for patients with initially unresectable hepatocellular carcinoma (GUIDANCE009)
2026 · figshare admin karger, Da-Long Yang, et al. · Figshare
Feasibility of achieving a tumor- and drug-free state through conversion therapy followed by curative hepatectomy for patients with initially unresectable hepatocellular carcinoma (GUIDANCE009)
2026 · Da-Long Yang, Yong-Rong Liang, et al. · Liver Cancer
Comparison of Survival Between Patients with Hepatocellular Carcinoma Beyond the “Up-to-7” Criterion Who Received Adjuvant PD-1 Inhibitors or Active Surveillance: A Target Trial Emulation Study
2026 · Jia-Yong Su, Zhen Liu, et al. · Journal of Clinical and Translational Hepatology
PDF
Progression-free survival as a potential surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma (GUIDANCE008)
2026 · Jin-Wei Wu, Da-Long Yang, et al. · Scientific Reports
PDF
The SAGES scoring model leads to personalized treatment via the combination of TACE, TKIs and ICIs for unresectable hepatocellular carcinoma
2026 · Hesheng Lin, Xueyao Wang, et al. · Frontiers in Immunology
PDF
CK7-positive hepatocellular carcinoma represents a distinct subtype: a retrospective cohort study
2026 · Xionglin Liu, Jindu Li, et al. · BMC Cancer
Association of environmental chemical exposure with metabolic dysfunction-associated steatotic liver disease: a cross-sectional and network toxicology analysis
2026 · Guodong Yang, Wenli He, et al. · European journal of medical research
Adjuvant camrelizumab for hepatocellular carcinoma patients with high risk of recurrence after curative hepatectomy: a retrospective multicenter study
2026 · Lei-Po Lin, Jia-Yong Su, et al. · European Journal of Gastroenterology & Hepatology
Sintilimab as adjuvant therapy for high-risk hepatocellular carcinoma after curative resection: a multicentric retrospective cohort study
2025 · Xiao-Ling Xu, Jia-Yong Su, et al. · European Journal of Gastroenterology & Hepatology
Works count: 33
Citation count: 88
H-index: 5
I10-index: 2
Year
Topic
Type